Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

1. Evaluate the maximum tolerated dose of oral daily thalidomide along with Paclitaxel (100 mg/m\^2 as a 3-hour infusion weekly \* 2, every 21 days) and oral estramustine phosphate (140 mg by mouth three times/day 5 days per week \* 2 weeks, every 21 days) for patients with metastatic androgen-independent prostate carcinoma. 2. Evaluate the efficacy of this regimen for patients with metastatic Androgen-Independent Prostate Cancer who failed up to two prior non-paclitaxel containing chemotherapy regimens, as measured by: * 2A. The objective response rate and 'prostate-specific antigen (PSA) response rate' of the combination treatment in patients with AI-PCa progressing after chemotherapy. * 2B. Secondary endpoints: calculate time to disease progression, effect on performance status, analgesic consumption, and survival. 3. To evaluate the toxicity of the combination treatment in patients with metastatic AI-PCa progressing after chemotherapy.